Transcatheter aortic valve replacement (TAVR) is a
relatively new technology in the field of medical science. It is a less
invasive method of replacing heart valve without undergoing the conventional
by-pass surgery. Aortic valve replacement typically requires open heart
surgery, thus it disqualifies patients who are at high risk for the process or
are too weak to undergo a surgery. As a result, the market of heart valve
surgical procedures is witnessing a continuous decline as more and more
patients requiring valve replacement are at risk for a surgical treatment. This
shortcoming of the traditional surgical method has paved way for the popularity
and adoption of TAVR. It was first commercially launched in Europe in 2007 and
later in the United States. The market for TAVR is regarded to be promising
with immense growth opportunities and unmet demand to cater to.
Request a sample of
this report @ http://www.orbisresearch.com/contacts/request-sample/58796 .
Rise in economic development, increasing old age
population, growing obese population, and increase of aortic stenosis patients
are some of the key drivers fueling the development of the global TAVR market.
Growth of this market is largely dependent on macro indicators, like global GDP
and global healthcare expenditure.
Purchase a copy of
Global Transcatheter Aortic Valve
Replacement (TAVR) Market visit @
http://www.orbisresearch.com/contact/purchase/58796
For more information contact sales@orbisresearch.com .
This report analyzes the development of "global TAVR
market", with special focus on the major markets like the United States
and Europe. The major market trends and drivers that facilitate the growth of
this market as well as the challenges it is facing are also analyzed in this
report. The top players operating in the TAVR industry include Edward
Lifesciences, Medtronic and St. Jude Medical and these companies have been
profiled in the report highlighting their key financials and business
strategies for growth and market expansion.
Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-transcatheter-aortic-valve-replacement-tavr-market-outlook-to-2019
.
Some points from TOC:
1. Market Overview
2. TAVR Market Analysis
2.1 Global Market
-TAVR Market Value: Actual & Forecast
-Implants Sold: Actual & Forecast
2.2 Regional Markets
2.2.1 US Market
-TAVR Market Value: Actual & Forecast
-Implants Sold: Actual & Forecast
-Patients at High Risk: Actual & Forecast
-Implants by Patient Type: Actual & Forecast
-Implants by Access Route: Actual & Forecast
2.2.2 Outside US Market
-TAVR Market Value: Actual & Forecast
-Patients at High Risk: Actual & Forecast
-EU Implants Sold: Actual & Forecast
-EU Implants by Patient Type: Actual & Forecast
-EU Implants by Access Route: Actual & Forecast
2.1 Global Market
-TAVR Market Value: Actual & Forecast
-Implants Sold: Actual & Forecast
2.2 Regional Markets
2.2.1 US Market
-TAVR Market Value: Actual & Forecast
-Implants Sold: Actual & Forecast
-Patients at High Risk: Actual & Forecast
-Implants by Patient Type: Actual & Forecast
-Implants by Access Route: Actual & Forecast
2.2.2 Outside US Market
-TAVR Market Value: Actual & Forecast
-Patients at High Risk: Actual & Forecast
-EU Implants Sold: Actual & Forecast
-EU Implants by Patient Type: Actual & Forecast
-EU Implants by Access Route: Actual & Forecast
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Increasing Ageing Population
3.1.2 Rising Global Healthcare Expense
3.1.3 Increasing Obese Population
3.1.4 Global Economic Development
3.1.5 Increasing Prevalence of Inoperable Aortic Stenosis
3.2 Challenges
3.2.1 Regulatory Issues
3.2.2 Associated High Risk
3.2.3 High Cost of TAVR Devices
3.3 Key Trends
3.3.1 Favorable Reimbursement in Europe
3.3.2 Positive Outcomes from SAPIEN 3
3.3.3 TAVR for Low Risk Patients
3.3.4 Edwards Dominates TAVR Market
3.1 Growth Drivers
3.1.1 Increasing Ageing Population
3.1.2 Rising Global Healthcare Expense
3.1.3 Increasing Obese Population
3.1.4 Global Economic Development
3.1.5 Increasing Prevalence of Inoperable Aortic Stenosis
3.2 Challenges
3.2.1 Regulatory Issues
3.2.2 Associated High Risk
3.2.3 High Cost of TAVR Devices
3.3 Key Trends
3.3.1 Favorable Reimbursement in Europe
3.3.2 Positive Outcomes from SAPIEN 3
3.3.3 TAVR for Low Risk Patients
3.3.4 Edwards Dominates TAVR Market
For any enquires
before buying, connect with us @ enquiry@orbisresearch.com
No comments:
Post a Comment